An observational study in Non-small Cell Lung Cancer Stage ⅢA and Non-small Cell Lung Cancer Stage IIIB, sponsored by West China Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-01.
Sponsored by West China Hospital · Observational
to explore the impact of preoperative neoadjuvant immunotherapy on perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 250 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →West China Hospital is the lead sponsor of 484 studies on the registry; 241 are open to participants now.
Counted across the registry records on this site, refreshed daily.
locally advanced NSCLC meeting the above crateria
Confirmed as primary lung cancer through cytology or histological examination;
ECOG score of 0 or 1; ③ 18 years old or above;
Received imaging examination, with a preliminary clinical staging of stage III;
Exclusion Criteria:
Patients with combined small cell lung cancer; ② Patients with severe liver/kidney dysfunction, cardiovascular disease, or systemic immune disorders;
patients received different cycles of neoadjuvant chemoimmunotherapy
Other: cycles of neoadjuvant therapy and duration of waiting for surgery
the duration of before patients received surgery after neoadjuvant chemoimmunotherapy
Other: cycles of neoadjuvant therapy and duration of waiting for surgery
We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
major pathological remission
proportion of patients with no more than 10% residual viable tumor cells; patients who showed no viable tumor in the lung primary setting but lymph nodes show viable metastatic carcinoma were also classified as MPR
Time frame: one month
pathological complete remission
proportion of patients without residual viable tumor cell on evaluation of resected lung cancer specimens including all sampled regional lymph nodes
Time frame: one month
survival time
time since diagnosed with NSCLC
Time frame: 5 years
No study locations are listed for this record.
Plan to share: No — The datasets are available upon reasonable request.
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
West China Hospital